Show simple item record

dc.contributor.authorZephyr, Jacqueto
dc.contributor.authorYilmaz, Nese Kurt
dc.contributor.authorSchiffer, Celia A.
dc.date2022-08-11T08:08:11.000
dc.date.accessioned2022-08-23T15:45:26Z
dc.date.available2022-08-23T15:45:26Z
dc.date.issued2021-11-17
dc.date.submitted2022-01-12
dc.identifier.citation<p>Zephyr J, Kurt Yilmaz N, Schiffer CA. Viral proteases: Structure, mechanism and inhibition. Enzymes. 2021;50:301-333. doi: 10.1016/bs.enz.2021.09.004. Epub 2021 Nov 17. PMID: 34861941; PMCID: PMC8595904. <a href="https://doi.org/10.1016/bs.enz.2021.09.004">Link to article on publisher's site</a></p>
dc.identifier.issn1874-6047 (Linking)
dc.identifier.doi10.1016/bs.enz.2021.09.004
dc.identifier.pmid34861941
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27529
dc.description.abstractViral proteases are diverse in structure, oligomeric state, catalytic mechanism, and substrate specificity. This chapter focuses on proteases from viruses that are relevant to human health: human immunodeficiency virus subtype 1 (HIV-1), hepatitis C (HCV), human T-cell leukemia virus type 1 (HTLV-1), flaviviruses, enteroviruses, and coronaviruses. The proteases of HIV-1 and HCV have been successfully targeted for therapeutics, with picomolar FDA-approved drugs currently used in the clinic. The proteases of HTLV-1 and the other virus families remain emerging therapeutic targets at different stages of the drug development process. This chapter provides an overview of the current knowledge on viral protease structure, mechanism, substrate recognition, and inhibition. Particular focus is placed on recent advances in understanding the molecular basis of diverse substrate recognition and resistance, which is essential toward designing novel protease inhibitors as antivirals.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=34861941&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595904/
dc.subjectCoronavirus
dc.subjectDrug resistance
dc.subjectEnterovirus
dc.subjectFlavivirus
dc.subjectHCV
dc.subjectHIV-1
dc.subjectHTLV-1
dc.subjectProtease inhibitors
dc.subjectSubstrate envelope
dc.subjectViral protease
dc.subjectBiochemistry, Biophysics, and Structural Biology
dc.subjectEnzymes and Coenzymes
dc.subjectInfectious Disease
dc.subjectVirology
dc.subjectVirus Diseases
dc.subjectViruses
dc.titleViral proteases: Structure, mechanism and inhibition
dc.typeBook Chapter
dc.source.booktitleThe Enzymes
dc.source.volume50
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/covid19/330
dc.identifier.contextkey27296608
html.description.abstract<p>Viral proteases are diverse in structure, oligomeric state, catalytic mechanism, and substrate specificity. This chapter focuses on proteases from viruses that are relevant to human health: human immunodeficiency virus subtype 1 (HIV-1), hepatitis C (HCV), human T-cell leukemia virus type 1 (HTLV-1), flaviviruses, enteroviruses, and coronaviruses. The proteases of HIV-1 and HCV have been successfully targeted for therapeutics, with picomolar FDA-approved drugs currently used in the clinic. The proteases of HTLV-1 and the other virus families remain emerging therapeutic targets at different stages of the drug development process. This chapter provides an overview of the current knowledge on viral protease structure, mechanism, substrate recognition, and inhibition. Particular focus is placed on recent advances in understanding the molecular basis of diverse substrate recognition and resistance, which is essential toward designing novel protease inhibitors as antivirals.</p>
dc.identifier.submissionpathcovid19/330
dc.contributor.departmentSchiffer Lab
dc.contributor.departmentDepartment of Biochemistry and Molecular Pharmacology
dc.source.pages301-333


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record